ZA200708372B - KIM-1 antibodies for treatment of Th2-mediated conditions - Google Patents

KIM-1 antibodies for treatment of Th2-mediated conditions

Info

Publication number: ZA200708372B
Authority: ZA; South Africa
Prior art keywords: kim; antibodies; treatment; mediated conditions; mediated
Prior art date: 2005-03-02

Application number

ZA200708372A

Other languages

English (en)

Inventor

Paul D Rennert

Bailly Veronique

Mccoon Patricia

Lugovskoy Alexey

Original Assignee

Biogen Idec Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-02

Filing date

2007-10-01

Publication date

2008-12-31

2007-10-01 Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc

2008-12-31 Publication of ZA200708372B publication Critical patent/ZA200708372B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Otolaryngology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ZA200708372A 2005-03-02 2007-10-01 KIM-1 antibodies for treatment of Th2-mediated conditions ZA200708372B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US65778905P	2005-03-02	2005-03-02

Publications (1)

Publication Number	Publication Date
ZA200708372B true ZA200708372B (en)	2008-12-31

Family

ID=36648475

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200708372A ZA200708372B (en)	2005-03-02	2007-10-01	KIM-1 antibodies for treatment of Th2-mediated conditions

Country Status (15)

Country	Link
US (2)	US8206705B2 (de)
EP (2)	EP1865985B1 (de)
JP (2)	JP2008531719A (de)
KR (1)	KR101213894B1 (de)
CN (2)	CN101166542A (de)
AT (1)	ATE478707T1 (de)
AU (2)	AU2006218489B2 (de)
BR (1)	BRPI0608254A2 (de)
CA (1)	CA2599967C (de)
DE (1)	DE602006016413D1 (de)
HK (1)	HK1118007A1 (de)
IL (1)	IL185653A (de)
NZ (1)	NZ562045A (de)
WO (1)	WO2006094134A2 (de)
ZA (1)	ZA200708372B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008064031A2 (en) *	2006-11-13	2008-05-29	Government Of The United States, As Represented Bythe Secretary Of The Department Of Health And Human Services	Potent activation of antigen presenting cells by the hepatitis a virus cellular receptor 1 and its role in the regulation of immune responses
US10654916B2 (en)	2011-04-21	2020-05-19	The Regents Of The University Of California, A California Corporation	Compositions and methods for the treatment of neuromyelitis optica
BR112018008390A2 (pt) *	2015-10-30	2018-11-27	Aleta Biotherapeutics Inc	composições e métodos para transdução tumoral
MA43135A (fr)	2015-10-30	2018-09-05	Aleta Biotherapeutics Inc	Compositions et méthodes pour le du traitement du cancer

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
DE3883899T3 (de)	1987-03-18	1999-04-22	Sb2, Inc., Danville, Calif.	Geänderte antikörper.
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
WO1992022653A1 (en)	1991-06-14	1992-12-23	Genentech, Inc.	Method for making humanized antibodies
AU688751B2 (en)	1993-01-12	1998-03-19	Biogen Idec Ma Inc.	Recombinant anti-VLA4 antibody molecules
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
US5622861A (en)	1994-08-05	1997-04-22	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant DNA encoding hepatitis A virus receptor
US6066322A (en)	1995-03-03	2000-05-23	Millennium Pharmaceuticals, Inc.	Methods for the treatment of immune disorders
WO1996034096A1 (en)	1995-04-28	1996-10-31	Abgenix, Inc.	Human antibodies derived from immunized xenomice
DE19541844C1 (de)	1995-11-09	1997-07-24	Gsf Forschungszentrum Umwelt	Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6165733A (en)	1996-05-23	2000-12-26	Chiron Corporation	γ II adaptin
EA004402B1 (ru)	1996-05-24	2004-04-29	Байоджен, Инк.	Модуляторы регенерации тканей
WO1998020110A1 (en)	1996-11-01	1998-05-14	Human Genome Sciences, Inc.	HUMAN MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MAdCAM-1) AND SPLICE VARIANTS THEREOF
ATE387495T1 (de)	1996-12-03	2008-03-15	Amgen Fremont Inc	Vollkommen humane antikörper die egfr binden
DE69736984T2 (de)	1996-12-06	2007-09-13	Vertex Pharmaceuticals Inc., Cambridge	Inhibitoren des interleukin-1-beta konvertierenden enzyms
PT1049717E (pt)	1998-01-23	2007-05-31	Hoffmann La Roche	Anticorpos contra a il-12 humana.
KR20010041765A (ko)	1998-03-11	2001-05-25	가마쿠라 아키오	ＩｇＥ 항체생산 억제제 및 자기면역질환 억제제
US6228642B1 (en)	1998-10-05	2001-05-08	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US8288322B2 (en)	2000-04-17	2012-10-16	Dyax Corp.	Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
NZ523475A (en)	2000-06-16	2004-09-24	Biogen Inc	Renal regulatory elements and methods of use thereof
DE60224275T2 (de) *	2001-06-01	2008-12-11	Biogen Idec Ma Inc., Cambridge	Moleküle und verfahren zur inhibierung der freisetzung von kim-1
MXPA04000034A (es)	2001-06-29	2005-11-23	Univ Leland Stanford Junior	Genes regulatorios de celulas t metodos para utilizar los mismos.
US7838220B2 (en)	2001-06-29	2010-11-23	The Board Of Trustees Of The Leland Stanford Junior University	T cell regulatory genes associated with immune disease
EP1434881A4 (de)	2001-09-17	2005-10-26	Protein Design Labs Inc	Verfahren zur diagnose von krebszusammensetzungen und verfahren zum screening auf krebsmodulatoren
WO2003042661A2 (en)	2001-11-13	2003-05-22	Protein Design Labs, Inc.	Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US7687454B2 (en)	2001-12-03	2010-03-30	The University Of British Columbia	Effectors of innate immunity determination
CA2474497C (en)	2002-01-30	2013-12-03	The Brigham And Women's Hospital, Inc.	Compositions and methods related to tim-3, a th1-specific cell surface molecule
JP2005535294A (ja)	2002-03-19	2005-11-24	キュラジェンコーポレイション	治療ポリペプチド、それをコードする核酸、および使用方法
GB0215509D0 (en)	2002-07-04	2002-08-14	Novartis Ag	Marker genes
CN1835769B (zh)	2002-12-30	2011-06-29	比奥根艾迪克Ma公司	Kim-1拮抗剂及其在免疫系统调节中的应用
CA2519528C (en)	2003-03-19	2016-01-26	Abgenix, Inc.	Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
US20050119210A1 (en)	2003-05-20	2005-06-02	Xiaobing Be	Compositions and methods for diagnosing and treating cancers
TW200539890A (en)	2004-03-12	2005-12-16	Brigham & Womens Hospital	Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
MXPA06010844A (es)	2004-03-24	2007-05-08	Telos Pharmaceuticals Llc	Composiciones adyuvantes para mejorar respuestas inmunes a vacunas y metodos de uso.
US8025557B2 (en)	2009-02-27	2011-09-27	Illinois Tool Works Inc.	Sanding clay

2006
- 2006-03-02 DE DE602006016413T patent/DE602006016413D1/de active Active
- 2006-03-02 BR BRPI0608254-8A patent/BRPI0608254A2/pt not_active IP Right Cessation
- 2006-03-02 EP EP06736714A patent/EP1865985B1/de active Active
- 2006-03-02 WO PCT/US2006/007441 patent/WO2006094134A2/en active Application Filing
- 2006-03-02 KR KR1020077022608A patent/KR101213894B1/ko not_active Expired - Fee Related
- 2006-03-02 US US11/817,638 patent/US8206705B2/en not_active Expired - Fee Related
- 2006-03-02 NZ NZ562045A patent/NZ562045A/en not_active IP Right Cessation
- 2006-03-02 AT AT06736714T patent/ATE478707T1/de not_active IP Right Cessation
- 2006-03-02 EP EP10173620.5A patent/EP2251037B1/de not_active Not-in-force
- 2006-03-02 CN CNA2006800139893A patent/CN101166542A/zh active Pending
- 2006-03-02 CN CN201410043208.1A patent/CN103751780A/zh active Pending
- 2006-03-02 AU AU2006218489A patent/AU2006218489B2/en not_active Ceased
- 2006-03-02 JP JP2007558223A patent/JP2008531719A/ja not_active Withdrawn
- 2006-03-02 CA CA2599967A patent/CA2599967C/en not_active Expired - Fee Related
2007
- 2007-09-02 IL IL185653A patent/IL185653A/en not_active IP Right Cessation
- 2007-10-01 ZA ZA200708372A patent/ZA200708372B/xx unknown
2008
- 2008-06-19 HK HK08106807.2A patent/HK1118007A1/xx not_active IP Right Cessation
2011
- 2011-05-24 AU AU2011202405A patent/AU2011202405B2/en not_active Ceased
2012
- 2012-03-28 JP JP2012073852A patent/JP2012131825A/ja active Pending
- 2012-04-04 US US13/439,413 patent/US20130089539A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL185653A0 (en)	2008-01-06
ATE478707T1 (de)	2010-09-15
JP2008531719A (ja)	2008-08-14
BRPI0608254A2 (pt)	2009-12-08
US20130089539A1 (en)	2013-04-11
US20100150905A1 (en)	2010-06-17
EP2251037B1 (de)	2015-01-14
HK1118007A1 (en)	2009-01-30
KR101213894B1 (ko)	2012-12-20
EP1865985A2 (de)	2007-12-19
CN101166542A (zh)	2008-04-23
JP2012131825A (ja)	2012-07-12
US8206705B2 (en)	2012-06-26
DE602006016413D1 (de)	2010-10-07
IL185653A (en)	2013-04-30
EP2251037A1 (de)	2010-11-17
WO2006094134A3 (en)	2006-10-19
AU2006218489A1 (en)	2006-09-08
CA2599967A1 (en)	2006-09-08
CA2599967C (en)	2014-10-21
AU2006218489B2 (en)	2011-02-24
CN103751780A (zh)	2014-04-30
KR20070110411A (ko)	2007-11-16
NZ562045A (en)	2010-12-24
AU2011202405B2 (en)	2013-03-28
AU2011202405A1 (en)	2011-06-09
WO2006094134A2 (en)	2006-09-08
EP1865985B1 (de)	2010-08-25

Publication	Publication Date	Title
DE602006018057D1 (de)	2010-12-16	Substituierte chinolone und verwendungsverfahren
NO20083002L (no)	2008-08-14	Fremgangsmate for anvendelse av CD40-bindende forbindelser
ATE542823T1 (de)	2012-02-15	4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
IL233634A0 (en)	2014-08-31	Methods, compositions and kits for treating medical conditions
HRP20150175T1 (en)	2015-03-27	Means and methods for the treatment of tumorous diseases
EP1928453A4 (de)	2012-11-28	Verfahren und zusammensetzungen zur prävention und behandlung von nierenerkrankungen
EP2046315A4 (de)	2009-09-16	Therapeutische mittel zur behandlung maligner lymphome
ATE434620T1 (de)	2009-07-15	Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
ATE527241T1 (de)	2011-10-15	Pyridiazinonderivate zur behandlung von tumoren
ZA200705297B (en)	2009-01-28	Methods and compositions for treating amyloid related diseases
DE602005023172D1 (de)	2010-10-07	Hydantoinderivate zur behandlung von entzündlichen erkrankungen
TW200716224A (en)	2007-05-01	Method of indentifying therapeutic targets for the treatment of vulvovaginal atrophy
IL178435A0 (en)	2007-02-11	Beta-carbolines useful for treating inflammatory disease
MX2011012015A (es)	2012-04-30	Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
ZA200706113B (en)	2008-09-25	Method for the treatment of copper-bearing materials
WO2006081516A3 (en)	2007-05-03	USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS
ATE410166T1 (de)	2008-10-15	4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate zur behandlung von unfruchtbarkeit
MX2007010484A (es)	2007-10-15	Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.
HK1112157A1 (en)	2008-08-29	Apparatus for caring dead body
HK1118007A1 (en)	2009-01-30	Kim-1 antibodies for treatment of th2-mediated conditions
GB0620695D0 (en)	2006-11-29	Composition and methods for the treatment of nurdegenerative disease
EP1865952A4 (de)	2009-11-04	Histaminhaltige zusammensetzung zur behandlung von allergischen erkrankungen
ZA200610628B (en)	2008-06-25	Composition for diagnosing and treating circulatory system diseases
ATE448228T1 (de)	2009-11-15	Pyrrolopyrimidinderivate zur behandlung proliferativer krankheiten
ATE446757T1 (de)	2009-11-15	1-ä2h-1-benzopyran-2-one-8-ylü- piperazinderivative zur behandlung von bewegungsstörungen